Cascade Prodrug, Uneedle advance CPD100

Cascade Prodrug and Uneedle are partnering to test suprachoroidal delivery of CPD100 using Uneedle's Bella-Vue microneedle system for treating wet AMD.

For retina specialists managing an anti-VEGF treatment landscape defined by chronic injection burden, the announcement signals early-stage movement toward a mechanistically distinct, delivery-route-differentiated approach to wet AMD.

Note: This is a preclinical development update, not a clinical efficacy readout: CPD100 has not yet entered human testing, and no peer-reviewed data on the compound have been published.

Development and regulatory overview

According to the companies, Cascade's preclinical proof-of-concept program combining CPD100 with Bella-Vue delivery is already underway, with a goal of completing that work and supporting an initial INTERACT (INitial Targeted Engagement for Regulatory Advice on CBER/CDER producTs) meeting with the FDA in the fourth quarter of 2026.¹ Cascade said it is also pursuing funding to complete chemistry, manufacturing, and controls (CMC) work and nonclinical Good Laboratory Practice (GLP)–enabling studies needed to support an eventual Investigational New Drug (IND) application.¹

According to the release, the supporting preclinical rationale comes from in vitro work showing that low concentrations of CPD100 induced cell-cycle arrest and apoptosis in endothelial cells under hypoxic conditions while sparing retinal cell viability—an effect the companies say supports a targeted anti-angiogenic mechanism confined to hypoxic macular tissue.¹

Uneedle plans to present the collaboration and initial development progress publicly for the first time at the OIS 9th Retina Innovation Summit in Montreal on July 14, 2026.¹

Clinical context

Wet AMD remains a leading cause of severe vision loss in older adults, and intravitreal anti-VEGF therapy has been the standard of care for roughly two decades.² Despite substantial gains in vision preservation, the regimen imposes a well-documented burden: many patients require injections as frequently as every 4 to 8 weeks for years, and real-world registry data show a majority still need dosing intervals short enough to strain adherence and clinic capacity.²,³ Surveys of retina specialists have repeatedly identified reduced treatment burden and longer-acting or sustained-delivery options as the field's top unmet needs.² Suboptimal adherence has, in turn, been linked to inferior visual outcomes.⁴

Drug and delivery platform background

CPD100 is described by Cascade as a prodrug designed to act preferentially in hypoxic disease environments, in contrast to conventional anti-VEGF biologics that act regardless of local oxygen tension.¹ The company's public pipeline materials describe CPD100 as combining anti-angiogenic and anti-inflammatory activity, though these claims originate from company-disclosed sources rather than peer-reviewed publications and should be interpreted cautiously.

The suprachoroidal space (SCS) has drawn increasing interest as a delivery route because it allows targeted access to the choroid and outer retina while potentially limiting anterior-segment exposure compared with intravitreal injection.⁵ Uneedle's Bella-Vue is a silicon microneedle platform designed to access the SCS; the company said it has been evaluated in animal models (rabbits, pigs, and nonhuman primates) and in a phase 1 human study in wet AMD assessing feasibility, safety, and delivery accuracy.⁶ The SCS route already has regulatory precedent: in October 2021, the FDA approved triamcinolone acetonide injectable suspension (Xipere) for suprachoroidal use in uveitic macular edema, based on the phase 3 PEACHTREE trial, marking the first FDA approval of any therapy delivered into the suprachoroidal space.⁷,⁸ That approval established clinical and regulatory feasibility for SCS delivery generally, though Xipere is approved for a different indication (uveitic, not neovascular, macular edema) and delivers a corticosteroid rather than a hypoxia-targeted small molecule.

Interpretive framing

The collaboration represents an early-stage pairing of a novel mechanism with a delivery platform that has some precedent in ophthalmic use, but it stops well short of demonstrating clinical benefit. The available evidence for CPD100 itself is limited to sponsor-reported in vitro findings; efficacy and safety in the eye, let alone comparative benefit over existing anti-VEGF agents, remain untested. Prior experience with Bella-Vue provides some reassurance on delivery feasibility, but that experience is drawn from a different drug class (corticosteroid, in Xipere's case, plus preclinical tolerability data from Cascade's own suprachoroidal administration study) and cannot be assumed to generalize to CPD100's pharmacology or dosing requirements.

Limitations and next steps

Several gaps are notable. No human data on CPD100 have been generated or disclosed. The preclinical proof-of-concept study combining CPD100 with Bella-Vue is still ongoing, with no reported results. An INTERACT-FDA meeting—a preliminary, non-binding regulatory interaction—is only planned for the fourth quarter of 2026, and IND clearance would require additional CMC and GLP-enabling nonclinical work for which Cascade states it is still securing funding.¹ As a result, timelines to any human trial, let alone regulatory decision, are not yet established and are subject to change.

References

1. Cascade Prodrug and Uneedle Advance Collaboration to Enable Suprachoroidal Delivery of CPD100 for Wet AMD. GlobeNewswire. July 8, 2026. https://www.globenewswire.com/news-release/2026/07/08/3324377/0/en/Cascade-Prodrug-and-Uneedle-Advance-Collaboration-to-Enable-Suprachoroidal-Delivery-of-CPD100-for-Wet-AMD.html

2. Khanani AM, et al. Review of Neovascular Age-Related Macular Degeneration Treatment Options. Am J Manag Care. https://www.ajmc.com/view/review-of-neovascular-agerelated-macular-degeneration-treatment-options

3. Real-World Injection Intervals in Wet AMD. Retina Today. https://retinatoday.com/articles/2020-may-june/real-world-injection-intervals-in-wet-amd

4. Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in Neovascular Age-related Macular Degeneration. Ophthalmol Sci. 2023. https://www.ophthalmologyscience.org/article/S2666-9145(23)00153-7/fulltext

5. Suprachoroidal drug delivery: a versatile therapeutic platform. Expert Opin Drug Deliv. 2024. https://www.tandfonline.com/doi/full/10.1080/17425247.2024.2435461

6. Uneedle. Bella-Vue Suprachoroidal Injection. https://www.uneedle.com/silicon-microneedles/suprachoroidal-injection

7. XIPERE (triamcinolone acetonide injectable suspension) Prescribing Information. US FDA. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211950s000lbl.pdf

8. FDA Approves Drugs for Wet AMD, Macular Edema Due to Uveitis. Medscape. https://www.medscape.com/viewarticle/961565